Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.39 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.37 |
| ▸ | CDK2 | P24941 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734679 | 0.95 | POLB (0.56) | POLBSERPINA3ABCB1PDGFRACCNE1 | |
| SCHEMBL2734805 | 0.95 | POLB (0.56) | POLBSERPINA3ABCB1PDGFRACCNE1 | |
| SCHEMBL2734794 | 0.94 | POLB (0.58) | POLBBTN3A1SERPINA3ABCB1PDGFRA | |
| SCHEMBL2734814 | 0.94 | POLB (0.58) | POLBBTN3A1SERPINA3ABCB1PDGFRA | |
| SCHEMBL2734813 | 0.94 | POLB (0.55) | POLBSERPINA3ABCB1PDGFRACCNE1 | |
| SCHEMBL2734815 | 0.93 | POLB (0.54) | POLBSERPINA3ABCB1PDGFRACCNE1 | |
| SCHEMBL2734817 | 0.93 | POLB (0.54) | POLBSERPINA3ABCB1PDGFRACCNE1 | |
| SCHEMBL12339226 | 0.93 | POLB (0.57) | POLBBTN3A1SERPINA3ABCB1PDGFRA | |
| SCHEMBL2759937 | 0.93 | POLB (0.60) | POLBSERPINA3ABCB1PDGFRACCNE1 | |
| SCHEMBL2734816 | 0.92 | POLB (0.56) | POLBSERPINA3ABCB1PDGFRACCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2204374-A1 | Nucleoside phosphonates and analogs thereof for the treatment of HPV-infections | GILEAD SCIENCES, INC. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885BTN3A1 1044/4885SERPINA3 1896/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885BTN3A1 1044/4885SERPINA3 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.